XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events Aug 05, 2021 7:30am EDT
U.S. Food and Drug Administration has Granted Orphan Drug Designation to XOMA’s Licensed anti-TGFβ Asset NIS793 Jul 28, 2021 7:30am EDT
XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences Jul 15, 2021 4:00am EDT
XOMA Licensees to Present Significant Clinical Data at 2021 ASCO Annual Meeting May 21, 2021 8:00am EDT
XOMA Reports First Quarter 2021 Financial Results and Highlights Recent Operational Events May 06, 2021 7:30am EDT
